Compare Abbott Laboratories (ABT) vs The Coca-Cola Co K (KO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs The Coca-Cola Co K — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while The Coca-Cola Co K trades at $84.43 (market cap $361.62B). The key difference: The Coca-Cola Co K is far larger — about 2.2× Abbott Laboratories's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | KO | |
|---|---|---|
Market Cap | $166.94B | $361.62B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $84.14 |
52-Week Low | $82.57 | $65.67 |
Enterprise Value | $193.69B | $391.69B |
Dividend Yield | 2.63% | 2.52% |
Volume | — | 14,630,257 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Coca-Cola (KO) trades at $84.74, up 2.15% today, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported robust earnings, beating estimates for three consecutive quarters, with a net income margin of 27.8% in 2025. Recent news highlights steady demand and dividend reliability, with the stock near its consensus price target of $88.14.
KO offers a stable investment with consistent dividend growth and solid fundamentals, but faces risks from regional demand volatility and high valuation multiples. Analyst consensus is bullish, with 60% buy ratings, though the stock's current price proximity to resistance levels suggests limited near-term upside without new catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
